These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17056093)

  • 1. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
    Kovacs K; Horvath E; Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE
    Hum Pathol; 2007 Jan; 38(1):185-9. PubMed ID: 17056093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
    Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide.
    Felker J; Patterson B; Wrubel D; Janss A
    J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1413-1415. PubMed ID: 27815961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm.
    Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE; Horvath E; Kovacs K
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):552-3. PubMed ID: 16984254
    [No Abstract]   [Full Text] [Related]  

  • 5. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
    Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
    Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
    Bilbao I; Egaña N; García C; Olaizola I
    Endocrinol Diabetes Nutr; 2017 Dec; 64(10):564-566. PubMed ID: 29137963
    [No Abstract]   [Full Text] [Related]  

  • 7. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
    Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
    Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
    Strowd RE; Salvatori R; Laterra JJ
    J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
    Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
    Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
    Chen C; Yin S; Zhang S; Wang M; Hu Y; Zhou P; Jiang S
    Medicine (Baltimore); 2017 Nov; 96(47):e8733. PubMed ID: 29381964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
    Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
    Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide.
    van der Vlist A; Snijders TJ; Stades AME; Spliet WGM; De Vos FYFL
    Neth J Med; 2017 Dec; 75(10):451-454. PubMed ID: 29256415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel use of temozolomide in a patient with malignant prolactinoma.
    Byrne S; Karapetis C; Vrodos N
    J Clin Neurosci; 2009 Dec; 16(12):1694-6. PubMed ID: 19818629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
    Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
    Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
    Almalki MH; Aljoaib NN; Alotaibi MJ; Aldabas BS; Wahedi TS; Ahmad MM; Alshahrani F
    Hormones (Athens); 2017 Apr; 16(2):139-149. PubMed ID: 28742502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
    Barkhoudarian G; Palejwala SK; Ogunbameru R; Wei H; Eisenberg A; Kelly DF
    World Neurosurg; 2018 Oct; 118():118-124. PubMed ID: 30031177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine agonist-resistant prolactinomas.
    Oh MC; Aghi MK
    J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
    Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How effective is temozolomide for treating pituitary tumours and when should it be used?
    Halevy C; Whitelaw BC
    Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide: a novel treatment for pituitary carcinoma.
    Lim S; Shahinian H; Maya MM; Yong W; Heaney AP
    Lancet Oncol; 2006 Jun; 7(6):518-20. PubMed ID: 16750503
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.